MetLife director acquires 157 dividend shares

MetLife director Diana McKenzie acquired additional common shares via dividend reinvestment on deferred director compensation, increasing her direct holdings.

Available on EDGAR 09/10/2026 - 04:03 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

METLIFE INC (MET) director Diana McKenzie reported an acquisition of company common stock tied to director compensation. On September 8, 2026, she received 157 shares of common stock at an imputed price of $95.50 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this award, she directly holds 25,385 shares of MetLife common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Grant/Award: 157 shares

Grant/Award 1 txn

Insider MCKENZIE DIANA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	157	$95.50	$15K

Holdings After Transaction: Common Stock — 25,385 shares (Direct)

Holdings Before and After: Common Stock, 25,228 to 25,385 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Key Figures

Shares acquired: 157 shares Imputed price per share: $95.50 per share Shares owned after transaction: 25,385 shares

3 metrics

Shares acquired 157 shares Grant/award acquisition on September 8, 2026 via dividend reinvestment on deferred shares

Imputed price per share $95.50 per share Value attributed to the 157-share acquisition on September 8, 2026

Shares owned after transaction 25,385 shares Direct MetLife common stock holdings of Diana McKenzie following the reported acquisition

Key Terms

Imputed reinvestment of dividends, Deferred Compensation Plan for Non-Management Directors, deferred shares

3 terms

Imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan"

Deferred Compensation Plan for Non-Management Directors financial

"pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MetLife (MET) director Diana McKenzie report?

Diana McKenzie reported acquiring 157 shares of MetLife common stock on September 8, 2026, as a grant/award tied to reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

At what price were the new MetLife (MET) shares attributed in Diana McKenzie’s Form 4?

The 157 MetLife shares acquired by Diana McKenzie were attributed an imputed value of $95.50 per share, reflecting the price used for the reinvestment of dividends on her deferred shares under the director deferred compensation plan.

How many MetLife (MET) shares does Diana McKenzie hold after this transaction?

After the September 8, 2026 transaction, Diana McKenzie directly holds 25,385 shares of MetLife common stock, as reported in the Form 4 following the dividend reinvestment-related award.

Was Diana McKenzie’s MetLife (MET) Form 4 transaction under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and no footnote states that the transaction was made pursuant to a Rule 10b5-1 trading plan.

What is the nature of the MetLife (MET) shares acquired by Diana McKenzie in this Form 4?

The 157 shares represent an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The deferred shares were payable but their receipt was deferred by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCKENZIE DIANA

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		157	A	$95.5	25,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)